Download MendeleyStructure-Based Discovery of Potent CARM1 Inhibitors for Solid Tumor and Cancer Immunology Therapy.
Zhang, Z., Guo, Z., Xu, X., Cao, D., Yang, H., Li, Y., Shi, Q., Du, Z., Guo, X., Wang, X., Chen, D., Zhang, Y., Chen, L., Zhou, K., Li, J., Geng, M., Huang, X., Xiong, B.(2021) J Med Chem 64: 16650-16674
- PubMed: 34781683
- DOI: https://doi.org/10.1021/acs.jmedchem.1c01308
- Primary Citation of Related Structures:
7FAI, 7FAJ - PubMed Abstract:
CARM1 is a protein arginine methyltransferase and acts as a transcriptional coactivator regulating multiple biological processes. Aberrant expression of CARM1 has been related to the progression of multiple types of cancers, and therefore CARM1 was considered as a promising drug target. In the present work, we report the structure-based discovery of a series of N 1 -(3-(pyrimidin-2-yl)benzyl)ethane-1,2-diamines as potent CARM1 inhibitors, in which compound 43 displays high potency and selectivity. With the advantage of excellent tissue distribution, compound 43 demonstrated good in vivo efficacy for solid tumors. Furthermore, from the detailed immuno-oncology study with MC38 C57BL/6J xenograft model, we confirmed that this chemical probe 43 has profound effects in tumor immunity, which paves the way for future studies on the modulation of arginine post-translational modification that could be utilized in solid tumor treatment and cancer immunotherapy.
Organizational Affiliation:
Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, P. R. China.
